Skip to main content

Table 1 Clinical features and selected laboratory abnormalities of COVID-19 patients with or without Aspergillus infection

From: Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series

Variable

Aspergillus positive (n = 8)

Aspergillus negative (n = 96)

P value

Demographics

 Age, mean (SD), years

73 (13)

53 (15)

< 0.001

 Male sex, no. (%)

8 (100)

54 (56.3)

0.02

Underlying disease, no. (%)

 Any

7 (87.5)

36 (37.5)

0.008

 Hypertension

7 (87.5)

31 (32.3)

0.003

 Diabetes mellitus

2 (25)

11 (11.5)

0.262

 Heart disease

1 (12.5)

6 (6.3)

0.439

 COPD

2 (25)

2 (2.1)

0.029

 Cancer

0 (0)

1 (1.0)

1

 Immunodeficiency

0 (0)

0 (0)

–

 Chronic kidney disease

2 (25)

0 (0)

0.005

 Pregnancy

0 (0)

3 (3.1)

1

Smoking in the past 1 year, no. (%)

2 (25)

6 (6.3)

0.115

Severe/critical type, no. (%)

8 (100)

70 (72.9)

0.196

Complications, no. (%)

 ARDS

4 (50)

38 (39.6)

0.712

 Shock

0 (0)

0 (0)

–

 Liver damage

1 (12.5)

7 (7.3)

0.485

 Acute kidney injury

1 (12.5)

0 (0)

0.077

Treatment, no. (%)

 Mechanical ventilation

4 (50)

11 (11.5)

0.014

 ECMO

1 (12.5)

3 (3.1)

0.278

 CRRT

1 (12.5)

1 (1.0)

0.149

Corticosteroid treatment, no. (%)

6 (75)

57 (59.4)

0.475

 Maximum methylprednisolone equivalent dosage, median (IQR), mg/day

70 (5–80)

40 (0–60)

0.191

Administration of antiviral treatment

8 (100)

89 (92.7)

1

Initial antibiotic treatment, no./total (%)

6 (75)

46 (47.9)

0.269

 3rd-generation cephalosporin

0 (0)

7 (7.3)

1

 Fluoroquinolone

3 (37.5)

26 (27.1)

0.683

 β-Lactamase inhibitors

6 (75)

17 (17.7)

0.001

ICU admission, no./total (%)

8 (100)

18 (18.8)

0